Hims & Hers Health (NYSE:HIMS) Insider Irene Becklund Sells 8,411 Shares

Hims & Hers Health, Inc. (NYSE:HIMS) insider Irene Becklund sold 8,411 shares of the business’s stock in a transaction that occurred on Wednesday, December 17th. The stock was sold at an average price of $36.71, for a total transaction of $308,767.81. Following the sale, the insider directly owned 2,126 shares in the company, valued at approximately $78,045.46. This represents a 79.82% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Hims & Hers Health Stock Performance

Shares of NYSE HIMS traded down $0.23 during midday trading on Thursday, reaching $34.74. The company had a trading volume of 11,410,870 shares, compared to its average volume of 30,867,883. Hims & Hers Health, Inc. has a 1 year low of $23.97 and a 1 year high of $72.98. The business’s 50-day simple moving average is $42.69 and its 200 day simple moving average is $48.78. The company has a current ratio of 1.88, a quick ratio of 1.64 and a debt-to-equity ratio of 1.67. The stock has a market cap of $7.91 billion, a P/E ratio of 64.33, a P/E/G ratio of 7.29 and a beta of 2.41.

Hims & Hers Health (NYSE:HIMS) last released its earnings results on Monday, November 3rd. The company reported $0.06 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.09 by ($0.03). The firm had revenue of $598.98 million during the quarter, compared to analyst estimates of $578.99 million. Hims & Hers Health had a net margin of 6.05% and a return on equity of 24.67%. Hims & Hers Health’s revenue was up 49.2% on a year-over-year basis. During the same period in the previous year, the company earned $0.32 earnings per share. On average, analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Hims & Hers Health declared that its Board of Directors has authorized a share repurchase plan on Monday, November 17th that permits the company to repurchase $250.00 million in outstanding shares. This repurchase authorization permits the company to repurchase up to 3% of its shares through open market purchases. Shares repurchase plans are usually a sign that the company’s board believes its shares are undervalued.

Analyst Ratings Changes

A number of equities research analysts recently commented on HIMS shares. KeyCorp began coverage on Hims & Hers Health in a report on Tuesday, October 21st. They set a “sector weight” rating for the company. Barclays started coverage on shares of Hims & Hers Health in a research note on Monday, December 8th. They set an “overweight” rating and a $48.00 price objective for the company. BTIG Research reaffirmed a “buy” rating and issued a $85.00 price objective on shares of Hims & Hers Health in a report on Tuesday, November 4th. Wall Street Zen cut shares of Hims & Hers Health from a “hold” rating to a “sell” rating in a report on Saturday, November 8th. Finally, UBS Group set a $32.00 target price on Hims & Hers Health in a research note on Tuesday, November 4th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, ten have given a Hold rating and three have given a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $45.50.

Institutional Investors Weigh In On Hims & Hers Health

Several hedge funds have recently modified their holdings of the company. Quent Capital LLC acquired a new stake in shares of Hims & Hers Health during the 3rd quarter valued at about $28,000. Binnacle Investments Inc purchased a new position in Hims & Hers Health during the third quarter worth approximately $28,000. Virtus Advisers LLC acquired a new stake in Hims & Hers Health in the second quarter valued at approximately $26,000. Quaker Wealth Management LLC acquired a new stake in Hims & Hers Health in the second quarter valued at approximately $29,000. Finally, Bessemer Group Inc. increased its position in shares of Hims & Hers Health by 105.8% in the second quarter. Bessemer Group Inc. now owns 607 shares of the company’s stock valued at $30,000 after buying an additional 312 shares in the last quarter. 63.52% of the stock is owned by hedge funds and other institutional investors.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.